Skip to content

A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.

A Randomized Controlled Clinical Study of the Use of Vaginal Radiofrequency Therapy in Treatment of Stress Urinary Incontinence.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05570071
Enrollment
90
Registered
2022-10-06
Start date
2022-10-20
Completion date
2025-03-31
Last updated
2022-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Incontinence, Stress

Brief summary

To investigate the immediate, short-term and long-term efficacy of vaginal radiofrequency therapy in the treatment of stress urinary incontinence, and to compare the efficacy of pelvic floor electromyography combined with biofeedback therapy in stress urinary incontinence.

Detailed description

Before treatment, patients with mild and moderate stress urinary incontinence were diagnosed according to the diagnostic criteria through medical history inquiry and gynecological physical examination, and patients were screened according to the inclusion and exclusion criteria. After informing two treatment plans and signing the informed consent, they were randomly divided into vaginal radiofrequency therapy group and electrical stimulation combined biofeedback group. After being included in the test, one hour urine pad test was conducted, and IIQ-7, PISQ-12 and FSFI questionnaires were completed. IIQ-7, PISQ-12 and FSFI questionnaires were followed up 1, 3, 6 and 12 months after treatment. After 3 months and 1 year of treatment, 1 hour urine pad test was given again.

Interventions

DEVICEphysical therapy

medical treatment of pelvic floor

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

18-75 years old women with a sexual history, and patients with mild to moderate stress urinary incontinence.

Exclusion criteria

Severe cardiopulmonary insufficiency, acute pelvic inflammatory disease or other infectious stage, non-steroidal anti-inflammatory drugs and steroid hormones affecting collagen production factors, POP-Q-2 and above prolapse.

Design outcomes

Primary

MeasureTime frameDescription
Urine leakage in 1-hour pad testbefore therapymeasure the urine leakage in 1-hour pad test
Change from urine leakage at 3 months3months after therapymeasure the urine leakage in 1-hour pad test at 3 months
Change from urine leakage at 12 months12months after therapymeasure the urine leakage in 1-hour pad test at 12 months

Secondary

MeasureTime frameDescription
incontinence impact questionnaire short form,IIQ-7before therapyUrinary incontinence may affect daily activities, interpersonal relationships or personal emotions.The minimum value is 0,and the maximum value is 21. Higher scores mean a worse outcome.
pelvic organ prolapsed-incontinence sexual questionnaire, PISQ-12before therapyThe sexual desire,orgasm,pain,urine leakage in sex of the participants.The minimum value is 0,and the maximum value is 48.Higher scores mean a better outcome.
Female Sexual index,FSFIbefore therapySex frequency,sexual satisfaction, physiological factors, affective factor , sexual partner factor. The minimum value is 0,and the maximum value is 124.Higher scores mean a better outcome.

Contacts

Primary ContactLi Yan
yanliqy@163.com+860531-89268917
Backup ContactMiao Yuan
qyfckjys@163.com+860531-89268917

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026